To describe key findings relating to the natural history and heterogeneity of bipolar disorder (BD) relevant to the development of a unitary clinical staging model. Currently proposed staging models are briefly discussed, highlighting complementary findings, and a comprehensive staging model of BD is proposed integrating the relevant evidence.
Clinical Implications
• A developmental clinical staging approach represents an important advance supporting earlier and more accurate psychiatric diagnosis.
• Clinical staging of BD must consider both the natural history of the disorder and the heterogeneity of the diagnosis.
• A comprehensive evidence-based staging model of BD is important to advance early detection and intervention, as well as research aimed at identifying markers of illness predisposition and progression.
Limitations
• The proposed staging model is an aggregate view derived from research studies and will not apply to all high-risk offspring or patients with BD.
• The staging model will need to be refined and informed by future research advances.
O ver the past 25 years, advances in psychiatric research that have translated into real differences in outcomes for patients have not been realized. This disappointing reality is in part the result of our diagnostic approach. Current diagnostic systems emphasize presenting symptoms without considering the context, important risk factors, and neglecting what we know about the natural history of illness development. As of 2010, acknowledging these significant limitations, the National Institute of Mental Health has sought alternative strategies to diagnosis. 1 Further, the current approach is counter to other areas of medicine in which diagnosis is anchored in a solid understanding of the natural history of illness development and refined by the use of valid illness subtypes and individual risk factors to derive patient-specific predictions of illness risk, progression, treatment response, and overall prognosis.
Hope of progress in the psychiatry discovery landscape comes from the increasing recognition that clinical staging is a useful conceptual framework to refine the phenotype of illness along developmental lines. This approach supports the identification of markers of illness risk and progression, as well as stage-specific treatment targets. [2] [3] [4] [5] [6] As pointed out by Scott et al, 7 staging presupposes that illness evolves in an identifiable temporal progression of phases, that early intervention will be more effective, aiming to significantly prevent or delay illness progression and that treatments for the earlier phases of illness will be more acceptable to patients and have a higher benefit-to-risk ratio. The staging approach has been highly beneficial in the prevention and early identification of other complex (Gene × Environment) disorders, including diabetes, cardiovascular disease, and various forms of cancer.
In this paper, I summarize key findings about the natural history and heterogeneity of bipolar disorder (BD) relevant to clinical staging and discuss the currently debated approaches to staging, highlighting complementary aspects. I aim to help the reader understand the similarities and origins of the differences in published staging models of BD and propose a comprehensive staging framework based on the evidence to advance clinical and research outcomes.
Natural History and Heterogeneity of Bipolar Disorder
There is a wealth of evidence supporting that a recurrent episodic illness course is the hallmark of the classical form of BD (Kraepelinean manic depressive illness). 8 The quality of remission and the frequency of recurrences are known to vary substantially between patients; however, over time, there is no systematic change in cycle length (time from the onset of one episode to the onset of the next episode) and the previous course is the best predictor of recurrence risk for individual patients. 9, 10 While progressive worsening of the course is often assumed, 11 Oepen et al 12 discussed the statistical artifact that led to this erroneous conclusion. This episodic recurrent form of BD is known to be associated with an increased rate of recurrent mood disorders, but not schizophrenia in relatives, and a high response rate to long-term lithium, estimated at 80%. 13, 14 A recent large prospective study 15 of patients with classical BD reported that the morbidity index in lithium-treated patients remained stable for up to 20 years. Moreover, lithium response was found to cluster in affected members. 16 Recent imaging studies have shown that long-term lithium treatment in these patients is neuroprotective. [17] [18] [19] Reflecting the broadening of the diagnostic criteria (the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised, and beyond) and the preference to diagnose BD instead of psychotic disorders, 20 there has been increased debate about progressively shortened cycle lengths and recasting BD as typically a progressive deteriorating illness. 21 For example, using current diagnostic criteria, it has been estimated that the classical episodic lithium responsive subtype accounts for only 30% of patients in a typical Canadian subspecialty outpatient program. 22 These observations underscore the importance of considering heterogeneity and the need to identify valid subtypes of BD to advance research and clinical practice outcomes. 23 The classical episodic lithium responsive subtype now forms part of a much broader spectrum of BD. Evidence supports that subtypes defined by either prophylactic response or nonresponse to lithium differ in clinical course, family history, and neurobiological correlates. 21, 24, 25 Lithium nonresponsive subtypes are more chronic disorders that preferentially respond to either atypical neuroleptics (psychotic spectrum) or to lamotrigine (BD II, comorbid anxiety disorders). 10, 26 Psychotic spectrum BD has overlapping neurobiological findings with psychotic disorders 23 and a higher risk of chronic nonepisodic illnesses in family members, including schizophrenia. 23, 27 Further, imaging and genetic studies have shown reliable differences between lithium-responsive and lithium-nonresponsive BD. 10,13,28,29
Clinical Staging: Clinical At Risk and Patient Studies
Research led by those in the early psychosis field has provided the initial support for the use of clinical staging in psychiatry. This research has provided important evidence in help seeking, ultra-high-risk youth of delayed or decreased rates of illness progression (transition to psychosis), as well as earlier diagnosis and effectiveness of more benign early stage treatments. 30, 31 In a recent prospective follow-up report, predictors of transition to psychosis included longer duration of symptoms, disorders of thought content and negative symptoms, consistent with a wealth of previous reports. 32 Negative symptoms include affective flattening, anhedonia, apathy, and alogia, which overlap clinically with depressive spectrum presentations. A recent meta-analysis confirmed that youth at clinical or familial high-risk for psychosis show moderate cognitive deficits relative to control subjects and that these cognitive deficits predict transition to psychosis. 33 The highest rate of cognitive deficits were reported in subjects at both clinical and familial risk for psychosis.
The extension of the early psychosis staging approach to BD is an area of intensive current interest. 34 The possibility of pluripotential (shared) early stages across different disorders has been proposed based on a degree of overlap in nonspecific early risk syndromes. 7, 30, 35 However, this proposal is problematic in many ways. It ignores the welldocumented and striking differences in developmental history, early illness trajectories, and family history between prototypical schizophrenia and classical recurrent BD. The natural history of typical psychotic illness starts with neurodevelopmental disorders, including cognitive and motor deficits, [36] [37] [38] academic decline, [38] [39] [40] negative symptoms, and attenuated psychotic symptoms 41, 42 ; a positive family history in this model informs the risk status as an optional aspect only of the ultra-high-risk prodrome.
In contrast, the natural history of classical BD does not include cognitive and motor deficits nor academic decline through childhood. 36, 37, 43 In fact, people who develop classical BD have normal or gifted premorbid academic and social functioning. Further, the family history typically includes recurrent mood disorders, not chronic psychotic illnesses. 10, 44, 45 Granted there are intermediate clinical presentations and reports of overlapping genetic and neurobiological findings; however, in part this reflects the broadening of the BD concept 20,46 and assortative mating. 47, 48 Another challenge to the proposal of simply generalizing the early psychosis model to mood disorders is that BD is not diagnosed until the manifestation of the first-activated (hypomanic or manic) episode; however, the classical disorder almost always starts with depressive episodes. 49 Moreover, depressive episodes typically antecede the first diagnosable activated episode by many years. 9, 50, 51 Therefore, by analogy with the first-episode psychosis approach, focusing the effort in BD on describing the prodrome to first-episode mania would be too little too late and would ignore the characteristic differences in the natural history of BD. That is, we would be focusing too far down the illness course; years after the impact of debilitating melancholic depressive episodes, often associated with a substantial risk of suicide. 52, 53 Moreover, there is a significant risk of addiction contiguous with the index depressive episodes, worsening the prognosis. 54 Other proponents of clinical staging for BD have focused on differentiating earlier-from later-stage illness in adult patients meeting full diagnostic criteria for BD. [55] [56] [57] However, these studies consider neither the evidence of early antecedent risk syndromes nor the developmental illness trajectory leading up to the full-blown diagnosis of BD, as reported in several large prospective studies of the offspring of parents with BD. 51, [58] [59] [60] Specifically, crosssectional studies comparing patients with full-threshold BD, subdivided as being in the earlier or later stage of illness based on various definitions of duration, have shown evidence of a progression toward a pro-inflammatory state, increased oxidative stress, and a reduction in neurotrophic factors and neuroplasticity. 57, 61, 62 These biological candidate marker studies have been supported by evidence of a decline in cognitive functioning and an increase in burden of illness effects in cohorts of broadly defined adult patients with BD. 49 Kapczinski et al 63 have discussed the evidence of neuroprogression in patients with BD in the context of MacEwen's model of stress-related allostatic load theory of disease. 64 Specifically, they have postulated that the genetic diathesis for disease interacts with the burden of illness, including duration of illness, comorbidities (substance use and inflammatory diseases), and perhaps treatment effects to culminate in persistent structural and functional changes in the brain. These neuroanatomical and functional changes are associated with increased treatment refractoriness, worsening morbidity (quality of remission and shortened cycle length), and declining cognition, global functioning, and quality of life. Recently, they proposed to stage patients with BD using quantitative cut-off scores of important clinical variables (global functioning, number of episodes [≤7], age of onset [≤62 years], and time elapsed since first episode [≤128 months]), and associated biochemical markers. 55 The problem with this proposal is that it focuses solely on progression of end-stage established BD, rather than developing a staging model based on the full natural history of illness development. It equates to studying fullblown illness, compared with full-blown illness for a longer period, and neglects early risk syndromes.
Largely based on cross-sectional studies of adults with established illness, Conus et al 65 have modified a clinical staging model derived from high-risk psychosis research. This model attempts to describe the extent of disease onset and progression starting from well but at identifiable risk (stage 0) through to mild nonspecific symptoms (stage 1), first-episode mania (BD) (stage 2), persistent depressive or manic relapse or recurrences (stage 3), followed by chronic progressive BD (stage 4). While this is a more comprehensive approach than focusing on stages of fullblown (end-stage disorder), the problem with adapting this model to the evidence is several-fold. First, it collapses numerous discrete early clinical stages of illness development, as identified through longitudinal prospective high-risk studies, into a single very heterogeneous stage 1. 66 Second, it does not incorporate family history as a way to identify stage 0 high-risk, although a positive family history is the most robust risk factor predicting for at least classical BD 67, 68 ; without the context of positive family history, the early stages are too nonspecific and would yield a very high rate of false positives. That is, hypomanic, depressive, and anxiety symptoms are common in adolescent epidemiologic samples and do not predict for BD. 69 However, there are specific predictive early risk syndromes in youth with a confirmed family history that should be incorporated. 70, 71 Third, the first episode of BD is typically a depressive episode, occurring years on average before any diagnosable activated episode. 50 Therefore, the evidence strongly suggests that we need to substantially modify the staging model derived from studies in the psychosis field to align with the natural history and consider the heterogeneity of evolving BD.
Clinical Staging: Prospective High-Risk Studies
Given the very high heritability of classical BD, offspring of parents with confirmed illness are an important identifiable and informative high-risk group. During the last 20 years, there have been numerous independent prospective longitudinal studies of offspring of parents with BD assessed during the risk period, providing essential information to inform a clinical staging model of BD.
In a series of publications from our research group, summarizing prospective systematic observations of a cohort of offspring of well-characterized parents with BD, we reported important differences in early childhood antecedents and in the course of mood disorders between high-risk subgroups. 50, 58, [72] [73] [74] Specifically, children of parents with BD with an excellent response to long-term lithium (lithium responders) had a completely normal or gifted early developmental course. In contrast, the children of parents who failed to respond to lithium prophylaxis (lithium nonresponders) manifest childhood problems with cognition, emotional regulation, socialization, and neurodevelopmental disorders. Among high-risk offspring who developed major mood disorders, the offspring of lithium responders had an episodic remitting course and responded to lithium prophylaxis, while the offspring of lithium nonresponders had non-fully remitting mood disorders and responded preferentially to either prophylaxis with an anticonvulsant or an atypical antipsychotic. 75, 76 Moreover, the spectrum of end-stage disorders among the affected offspring of lithium responders was limited to mood disorders, while the offspring of lithium nonresponders manifested both mood and psychotic spectrum illnesses.
In both high-risk cohorts, early childhood antecedents predicting the development of mood disorders included anxiety and sleep disorders. 66 However, in the offspring of lithium nonresponders, attention deficit, learning disabilities, and cluster A traits were also frequent childhood risk antecedents. 77 Findings regarding the evolution of psychopathology from this Canadian longitudinal high-risk study have been replicated in other independent longitudinal high-risk studies. 41, 60, 71 These collective observations were recently distilled into a clinical staging model that was tested using multi-state models. 4, 54, 66 The analysis, based on up to 17 years of prospective clinical research observation, supported that BD develops in a sequence of predictable clinical phases; not all offspring manifest all stages, but once they enter the model they proceed in a forward sequence. The clinical staging model is an aggregate overview, and it should be remembered that not all high-risk offspring follow the model or proceed to end-stage illness.
Preliminary evidence for subtle differences in immunological (pro-inflammatory) 78,79 neurotrophic and neuroendocrine markers 80, 81 have been reported in high-risk offspring, compared with control subjects, and in high-risk offspring in the earlier, compared with the later phases of illness development. These findings lend support for the validity and use of the proposed clinical staging model. 82 The early clinical manifestations are nonspecific, in that they are seen in other illness trajectories, including psychotic disorders, internalizing and externalizing disorders, and substance use disorders. They can also be self-limited presentations in some children (not progressing to major psychiatric illness). However, it is the nature of the family history that brings important meaning to these otherwise nonspecific clinical presentations. The history of psychopathology in other family members and their response to specific treatments are important predictive factors aiding in the early differentiation of illness trajectories and in predicting treatment response in help-seeking symptomatic youth. For example, stimulants and antidepressants should either be avoided or, if used, kept to low doses, short duration, and closely monitored in symptomatic youth (attention problems, anxiety, and depressive symptoms) with a confirmed family history of BD. [83] [84] [85] [86] Other clinical implications pertain to the organization of youth mental health services. That is, it is now clear that psychiatric diagnoses are in flux in young people and cannot be taken as end-stage or stable-static disorders; rather early syndromes should be viewed as potential stops on the way to different-end destinations. 84, [87] [88] [89] Regarding research, this staging model considers heterogeneity of BD, based on the evidence that there may be both overlapping as well as important differences in the pathophysiology, course, treatment response, and prognosis between illness subtypes. Further, the developmentally sensitive phenotypic trajectory of the proposed staging model is well suited to studying markers of illness predisposition and progression, separating the primary disease process from burden of illness effects. 82 This model also allows for the testing of interactive hypotheses at critical stages, including the role of early adversity and important mediating or moderating psychosocial and biological (puberty) influences. [90] [91] [92] 
An Integrative Staging Model for Bipolar Disorder
As championed by McGorry and colleagues (see McGorry et al 3 and McGorry 6,93 ), clinical staging models, describing the development and progression of major psychiatric illnesses, can be very helpful in advancing both clinical practice and research efforts. Clinical staging should advance our ability to identify evolving serious psychiatric illness earlier on, place an individual patient on a continuum of illness development, and advance our search for markers of illness predisposition and progression. These findings will undoubtedly lead to the development of novel, specific treatments targeting earlier stages of illness development that may be more effective, acceptable, and less harmful, compared with later-stage treatments. However, the use of clinical staging for BD will depend on whether it is based on the totality of the evidence. Finally, clinical staging represents an important step toward reducing stigma by legitimizing these illnesses as heritable complex brain diseases and aligning the approach to treatment and research with the way we approach other medical disorders, while always being mindful of the importance to balance early identification against overdiagnosis of normative, transient, or self-resolving emotional symptoms in youth. 69, 84 We are at a vital crossroads in our efforts to advance psychiatric research, particularly regarding understanding and recognizing the development of mood disorders. A major leap forward would come through integrating the evidence from various perspectives into a unified comprehensive staging model. Essentially, the proposed integrative model (Figure 1 ) considers the very high heritability of classical BD, the ability of a confirmed family history to bring context to early, otherwise nonspecific risk syndromes, the replicated evidence that childhood risk syndromes (anxiety and sleep) predict subsequent mood disorders in highrisk youth, that neurodevelopmental disorders predict for more psychotic spectrum disorders, and the overwhelming evidence that BD typically onsets as major depressive disorder years prior to the first-activated episode. The limitations of any proposal must be discussed. There are sporadic cases of even the classical form of BD in people with no identified family history. 94 However, in the case of classical disorder, this would be the exception rather than the rule. Further, the proposed model would allow for the appropriate level of conservatism when identifying a person as at risk or in the early stages of BD, if the predictive weight of a confirmed family history is not present-that is, in the proposed model, stages 0 to 3 are reserved for people with a confirmed familial risk. Further, the proposed model incorporates evidence from what we know of the early course of classical, familial BD; however, it also applies to those people on the trajectory to psychotic spectrum disorders. In this way, the model would support research focused on predicting the first-activated episode, as well as research focused on understanding the progression of endstage illness phenotypes (stage 4A to stage 4B).
Conclusion
Adopting a comprehensive evidence-based model of BD would mean that developmental and adult psychiatry researchers would need to collaborate more intensively toward achieving their common and important end goals. This would also necessitate developing new measures that apply across the developmental course from childhood through adolescence and into adulthood. However, it can be argued that to a certain extent expediency and reticence to change (that is, sending out squadrons of trained raters rather than making diagnoses in the context of a comprehensive clinical assessment; maintaining the solitudes between child and adult psychiatry) have prevailed and contributed substantially to the lack of research advancement 95 -going forward we should abandon approaches that have not paid off and run counter to the evidence.
Even a century later, we can still learn from the wisdom of Kraepelin, who recognized that major psychiatric illnesses were familial brain diseases. Further, he recognized that, despite some overlap, there were fundamental differences between classical mood and psychotic disorders, as evidenced in divergent clinical phases of illness development, prognosis, and family history. 96, 97 He based hypotheses on careful longitudinal direct observation of patients, incorporating relevant knowledge of other medical diseases available at the time. Let us hope that we move on from here, learning from our own more recent history and from other medical advances, to translate research into important clinical gains for patients and their families.
